Info
Advances in Cancer Treatment : From Systemic Chemotherapy to Targeted Therapy / / by Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares
| Advances in Cancer Treatment : From Systemic Chemotherapy to Targeted Therapy / / by Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares |
| Autore | Cavalcanti Iago Dillion Lima |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021 |
| Descrizione fisica | 1 online resource (VIII, 109 p. 27 illus., 25 illus. in color.) |
| Disciplina | 616.994 |
| Soggetto topico |
Oncology
Internal medicine Pharmacy Cancer—Treatment Tumor markers Cancer Nanomedicine Internal Medicine Cancer Therapy Tumour Biomarkers Cancer Nanotechnology Oncologia Terapèutica Fisiologia patològica Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-68334-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Cancer: concepts and epidemiology -- A brief history of cancer -- What is Cancer? -- Cancer Epidemiology -- Cancer development and immunology -- Cell cycle -- Cell cycle control: the function of cyclins -- Cancer triggering agents -- Proto-oncogenes -- Tumor suppressor genes -- Development of tumor mass -- Cancer Immunology -- Discovery of tumor markers -- Cancer diagnosis -- Impact of the discovery of tumor markers -- Main tumor markers for cancer diagnosis -- Alpha-fetoprotein (AFP) -- Human Chorionic Gonadotropin (β-HCG) -- Mucin-like cancer-associated antigen (MCA) -- CA 15.3 -- Carcinoembryonic antigen (CEA) -- Bladder tumor antigen (BTA) -- Telomerase -- Nuclear matrix protein (NMP 22) -- Cyfra 21.1 -- Prostatic acid phosphatase (PAP) -- Prostate-specific antigen (PSA) -- CA 125 -- CA 19.9 -- p53 -- CA 72.4 -- K-ras -- HER2 -- Cancer staging -- Conventional cancer treatment -- Therapeutic modalities of cancer -- Surgery -- Radiotherapy -- Antineoplastic chemotherapy -- Classification of antineoplastic agents by cycle -- Specific cycle antineoplastics -- Nonspecific antineoplastic agents -- Classification of antineoplastic agents by chemical structure and function -- Alkylating agents -- Antimetabolites -- Plant-derived antineoplastics -- Antitumor antibiotics -- Chemotherapy toxicity -- Hematological toxicity -- Liver toxicity -- Cardiac toxicity -- Anthracyclines -- Fluoropyrimidine -- Taxanes -- Pulmonary toxicity -- Neurological toxicity -- Renal toxicity -- Gastrointestinal toxicity -- Metabolic changes -- Targeted therapies in cancer treatment -- Overexpressed receptors on tumor cells -- Immunotherapy -- Monoclonal antibodies -- Types of monoclonal antibodies -- Side effects of monoclonal antibodies -- Checkpoint Inhibitors -- Side effects of checkpoint inhibitors -- Cancer Vaccines -- Vaccines in cancer prevention -- Vaccines for the treatment of cancer -- Non-specific immunotherapies -- Tyrosine kinase inhibitors -- Imatinib -- Gefitinib -- Erlotinib -- Sorafenib -- Dasatinib -- Nilotinib -- Lapatinib -- Adverse events of tyrosine kinase inhibitors -- Conventional chemotherapy vs. targeted therapy -- Differences between conventional chemotherapy and targeted therapy -- Risks and benefits of conventional chemotherapy compared to targeted therapy -- Eligibility criteria for the indication of the targeted therapy -- Side effects of targeted therapy -- Can targeted therapy replace conventional chemotherapy? -- Targeted therapy associated with conventional chemotherapy -- Pharmaceutical nanotechnology applied to cancer -- Pharmaceutical nanotechnology -- Classification of nanosystems -- Liposomes -- Micelles -- Polymeric nanoparticles -- Solid lipid nanoparticles -- Magnetic nanoparticles -- Metal nanoparticles -- Main functions of nanosystems in cancer -- Pharmaceutical nanotechnology in cancer diagnosis -- Pharmaceutical nanotechnology for cancer treatment. |
| Record Nr. | UNINA-9910484989203321 |
Cavalcanti Iago Dillion Lima
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in nanomaterials-based cell biology research / / Yunfeng Lin, Ronghui Zhou, editors
| Advances in nanomaterials-based cell biology research / / Yunfeng Lin, Ronghui Zhou, editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (227 pages) |
| Disciplina | 610.284 |
| Soggetto topico |
Nanostructured materials - Health aspects
Nanomedicine Stem cells Cèl·lules mare Materials nanoestructurats Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-16-2666-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- About the Authors -- Chapter 1: Nanomaterials and Stem Cells for Bone Tissue Engineering -- 1.1 Introduction -- 1.2 Stem Cell Types Applied to Nanomaterial-Based Bone Regeneration -- 1.2.1 Mesenchymal Stem Cells (MSCs) -- 1.2.1.1 Bone Marrow Stromal Cells (BMSCs) -- 1.2.1.2 Adipose-Derived Stem Cells (ASCs) -- 1.2.1.3 Dental Pulp Stem Cells (DPSCs) -- 1.2.2 Other Types of Adult Stem Cells -- 1.3 Nanomaterials Applied to Stem Cell Osteogenic Differentiation -- 1.3.1 Polymeric Nanomaterials -- 1.3.2 Metal-Based Nanomaterials -- 1.3.3 Silica-Based Nanomaterials -- 1.3.4 Carbon-Based Nanomaterials -- 1.3.5 Nucleic Acid-Based Nanomaterials -- 1.3.6 Hydroxyapatite -- 1.4 Properties of Nanomaterials Affecting Osteogenic Differentiation and Bone Formation -- 1.4.1 Mechanical Properties -- 1.4.2 Porosity -- 1.4.3 Hydrophilicity -- 1.4.4 Biodegradability -- 1.4.5 Biocompatibility -- 1.5 Nanostructures and Scaffolds Applied to Bone Tissue Engineering -- 1.5.1 Nanopatterns -- 1.5.2 Microspheres/Nanospheres -- 1.5.3 Nanotubes -- 1.5.4 Nanofibers -- 1.5.5 Nanocomposites -- 1.6 Growth Factors and Molecular Pathways Involved in Osteogenic Differentiation and Bone Tissue Engineering -- 1.6.1 Bone Morphogenetic Protein (BMP) -- 1.6.2 Vascular Endothelial Growth Factor (VEGF) -- 1.6.3 Basic Fibroblast Growth Factor (bFGF) -- 1.6.4 Insulin-like Growth Factor-1 (IGF-1) -- 1.6.5 Other Growth Factors Related to Bone Regeneration -- References -- Chapter 2: The Application of Nanomaterial in Skeletal Muscle Regeneration -- 2.1 Introduction -- 2.2 The Research Progress of Nanoscaffold Materials in Skeletal Muscle Regeneration -- 2.2.1 The Research Progress of Nanofiber Scaffold in Skeletal Muscle Regeneration -- 2.2.1.1 Electrospinning Research Progress in Preparation of Nanofibers.
2.2.1.2 The Research Progress of Physical Cues of Nanofibers on Myogenesis -- 2.2.1.3 Biochemical Cues of Nanofibers on Myogenesis -- 2.2.1.4 The Research Progress of Electrical Conductivity of Nanofibers on Myogenesis -- 2.2.1.5 The Research Progress of PCL Scaffolds for Muscle Regeneration -- 2.2.1.6 Other Nanofiber Scaffold Research Progress for Muscle Regeneration -- 2.2.2 The Research Progress of Nanohydrogels in Skeletal Muscle Regeneration -- 2.2.3 The Research Progress of Nanofilm in Skeletal Muscle Regeneration -- 2.2.4 The Research Progress of Nanocomposite Materials in Skeletal Muscle Regeneration -- 2.2.5 Other Nanomaterial Research Progress in Skeletal Muscle Regeneration -- 2.3 The Research Progress of Nanoparticles in Skeletal Muscle Regeneration -- 2.3.1 The Research Progress of Au Nanoparticles in Myogenesis -- 2.3.2 The Research Progress of Nanotubes and Nanorods in Myogenesis -- 2.3.3 The Research Progress of Other Nanoparticles in Myogenesis -- 2.3.4 The Research Progress of Composite Nanoparticles in Myogenesis -- 2.4 Conclusion -- References -- Chapter 3: Application of Nanomaterials in Neurodegenerative Diseases -- 3.1 Introduction -- 3.2 BBB -- 3.3 Nanomaterials -- 3.3.1 Size -- 3.3.2 Shape -- 3.3.3 Charge -- 3.3.4 Delivery Methods -- 3.4 NDD -- 3.4.1 AD -- 3.4.2 PD -- 3.4.3 HD -- 3.4.4 Other -- 3.5 Conclusion -- References -- Chapter 4: Application of Nano Drug Delivery Systems in Inhibition of Tumors and Cancer Stem Cells -- 4.1 Introduction -- 4.2 Cancer Stem Cell -- 4.2.1 Cell Cycle Arrest -- 4.2.2 Drug Efflux -- 4.2.3 DNA Damage Tolerance and DNA Damage Repair -- 4.2.4 Epithelial Mesenchymal Transformation (EMT) -- 4.2.5 Tumor Microenvironment -- 4.3 Nano Drug Delivery Systems -- 4.3.1 Strengthen Drug Stability -- 4.3.2 Enhance Drug Targeting -- 4.3.3 Better Degradability -- 4.3.4 Increase Bioavailability of Drugs. 4.4 Liposomes -- 4.4.1 Overcoming the Quick Elimination by MPS -- 4.4.2 Constructing Active Targeting Liposomes -- 4.4.3 Realizing Triggered Release of Drug -- 4.4.4 Constructing Multifunctional Liposomes -- 4.5 Polymeric Micelles -- 4.5.1 Passive Targeting and Active Targeting Polymeric Micelles -- 4.5.2 Drug Co-delivery Systems -- 4.5.3 Environmentally Responsive Polymeric Micelles -- 4.6 Conclusion -- References -- Chapter 5: The Application and Problems of Tetrahedral Framework Nucleic Acids as a Drug Carrier in Biomedicine Fields -- 5.1 Introduction -- 5.2 DNA Nanostructures -- 5.2.1 The Concept of DNA Nanostructures -- 5.2.2 The Development of DNA Nanostructures -- 5.3 Tetrahedral Framework Nucleic Acids -- 5.3.1 Self-assembly -- 5.3.2 The Physical, Chemical, and Biological Characteristics -- 5.3.2.1 The Nanoscale and Editable -- 5.3.2.2 The Ability to Enter Cells -- 5.3.2.3 Biocompatibility and Biodegradability -- 5.3.2.4 High Chemical Reactivity and Multiple Modification Sites -- 5.3.3 The Application of tFNAs as a Drug Carrier in Biomedicine Fields -- 5.3.3.1 Transport Small-Molecule Drugs for Cancer Therapy -- 5.3.3.2 Transport Functional Nucleic Acids -- Antisense Oligodeoxynucleotide -- Antisense Peptide Nucleic Acid -- Aptamer -- siRNA -- Num, Dpt. -- 5.3.3.3 Transport Peptides and Proteins -- 5.3.3.4 Transport Multiple Drug Molecules -- 5.3.4 The Current Problems of tFNAs as a Drug Carrier in Biomedicine Fields We Faced -- 5.3.4.1 Improves the Stability of DNA Tetrahedron In Vivo -- 5.3.4.2 Improves the Cell Uptake Efficiency of DNA Tetrahedron -- 5.3.4.3 Improve the Synthetic Yield and Reduce the Synthesis Cost of DNA Tetrahedron -- 5.4 Conclusion -- References -- Chapter 6: Research Progress on Antibacterial Application with Nucleic Acid and Nucleic Acid Materials -- 6.1 Introduction -- 6.2 Nucleic Acid Aptamer. 6.3 Antisense Oligonucleotide (ASODN) and Antisense Peptide Nucleic Acid (PNA) -- 6.4 Combined Application of DNA Nanomaterials and Antisense Technology -- 6.5 Combination of DNA Nanostructures and Antibiotics -- 6.6 Combined Application of DNA Nanostructure and Metal Nanoparticles -- 6.7 Combined Application of DNA Nanostructure and Antimicrobial Peptide (AMP) -- 6.8 Antimicrobial Studies of Some Other Nucleic Acid or Analogues -- 6.9 Conclusion -- References -- Chapter 7: The Application of DNA Nanostructures in Vaccine Technology -- 7.1 Introduction -- 7.2 DNA Nanostructures -- 7.2.1 DNA Tetrahedron -- 7.2.2 DNA Nanotubes -- 7.2.3 DNA Hydrogel -- 7.2.4 DNA Nanoflower -- 7.2.5 DNA Dendrimer -- 7.3 Challenge and Prospect -- References. |
| Record Nr. | UNINA-9910495246303321 |
| Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Artificial cells, nanomedicine, and biotechnology
| Artificial cells, nanomedicine, and biotechnology |
| Pubbl/distr/stampa | London, United Kingdom : , : Informa Healthcare, , [2013]- |
| Disciplina | 610.28 |
| Soggetto topico |
Artificial cells
Blood substitutes Nanomedicine Biotechnology Nanotechnology Biocompatible Materials Nanomedicina Cèl·lules Biotecnologia Cellules artificielles Sang - Substituts Nanomédecine Biotechnologie Nanotechnologie |
| Soggetto genere / forma |
Periodicals.
Revistes electròniques. |
| ISSN | 2169-141X |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910154497203321 |
| London, United Kingdom : , : Informa Healthcare, , [2013]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer nanotheranostics . Volume 1 / / Muthupandian Saravanan, Hamed Barabadi, editors
| Cancer nanotheranostics . Volume 1 / / Muthupandian Saravanan, Hamed Barabadi, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (362 pages) : illustrations |
| Disciplina | 616.99406 |
| Collana | Nanotechnology in the Life Sciences |
| Soggetto topico |
Cancer - Treatment - Technological innovations
Nanomedicine Theranostic Nanomedicine Neoplasms - therapy Càncer Nanomedicina Oncologia Innovacions tecnològiques |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-74330-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910502986403321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Emerging trends in nanomedicine / / Sanjay Singh, editor
| Emerging trends in nanomedicine / / Sanjay Singh, editor |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (249 pages) |
| Disciplina | 610.28 |
| Soggetto topico |
Nanomedicine
Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-9920-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910485006703321 |
| Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Integrated omics approaches to infectious diseases / / Saif Hameed and Zeeshan Fatima (editors)
| Integrated omics approaches to infectious diseases / / Saif Hameed and Zeeshan Fatima (editors) |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (538 pages) |
| Disciplina | 616.9 |
| Soggetto topico |
Parasitology
Communicable diseases - Etiology Malalties infeccioses Etiologia Biologia molecular Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-16-0691-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910495232703321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanomedicine for cancer diagnosis and therapy / / Arshi Malik, Sarah Afaq and Mohammed Tarique (editors)
| Nanomedicine for cancer diagnosis and therapy / / Arshi Malik, Sarah Afaq and Mohammed Tarique (editors) |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (251 pages) |
| Disciplina | 616.994075 |
| Soggetto topico |
Nanomedicine
Cancer - Treatment - Technological innovations Nanomedicina Oncologia Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-7564-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- About the Editors -- 1: Nanoparticles for Cancer Therapy -- 1.1 Introduction -- 1.1.1 Cancer and its Types -- 1.1.2 Nanomedicine -- 1.2 Evolution of Cancer Therapy -- 1.2.1 Surgery and Adjuvant Therapies -- 1.2.2 Hormone Therapy -- 1.2.3 Immunotherapy -- 1.2.4 Cancer Therapy with Nanomedicine -- 1.3 Nanoparticles in Cancer Therapy -- 1.3.1 Protein Nanoparticles -- 1.3.2 Magnetic Nanoparticles -- 1.3.3 Inorganic Nanoparticles -- 1.3.4 Lipid Nanoparticles -- 1.3.5 Targeted Nanoparticles -- 1.3.6 Polymeric Nanoparticles -- 1.3.7 Multifunctional Nanoparticles -- 1.3.8 Quantum Dots -- 1.3.9 DNA Nanoparticles -- 1.4 Pharmacokinetics of Cancer Nanodrug Carriers -- 1.5 Cancer Nanomedical Research -- 1.5.1 Initial Advancements in Nanoparticle Research -- 1.5.2 Nanomedical Research Using Plant-Derived Compounds -- 1.5.3 Nanomedical Research Using Gene Therapeutic Strategies -- 1.5.4 Nanomedical Research Using In Vivo Imaging Techniques -- 1.5.5 Mainstream Research in the ``Golden Age´´ of Nanotechnology -- 1.5.6 Nanomedical Research Using Computational and Nanobioinformatic Tools -- 1.6 Nanomedicine in Cancer Diagnosis and Treatment -- 1.6.1 Immunoassays Using Nanomaterial-Embedded Microchips -- 1.6.2 In Vivo Imaging Using Nanoparticle Contrast Agents -- 1.6.3 Theranostic Nanomedicine -- 1.6.4 Cancer Nanodrug Release Systems and Personalized Cancer Nanomedicine -- 1.7 Current Research and Prospects -- 1.7.1 Smart Nanocarrier-Based Drug-Delivery Systems for Cancer Therapy -- 1.7.2 RNA Delivery Using Nanoparticles -- 1.7.3 Nanobots -- 1.8 Concluding Remarks -- References -- 2: Strategies for Improving the Efficiency of Nanomaterials -- 2.1 Introduction -- 2.2 Strategies for the Improvement of Nanomaterials -- 2.2.1 Photocatalytic Efficiency -- 2.2.2 Therapeutic Efficiency.
2.2.2.1 Strategic Improvement of Nanomaterials for Enhanced Permeability and Retention (EPR) Effects -- 2.2.2.2 Strategic Improvement of Nanomedicine for Improved Drug Delivery Systems -- Liposome Based Nanoformulation -- Nanoemulsions -- Solid Lipid Nanoparticles (SLN) -- Strategies for Organelles Specific Targeting of Nanodrugs -- Virus Based Nanoformulation -- 2.2.2.3 Photoactivated Nanomaterials for Photodynamic and Photothermal Therapy (PDT/PTT) -- 2.2.2.4 Mesoporous Silica Nanoparticles (MSNP) -- 2.2.2.5 Dendrimers -- 2.2.3 Engineering Nanoparticles to Evade the Multidrug Resistance (MDR) in Cancer -- 2.2.4 Nanoparticle-Based Combination Therapy -- 2.3 Conclusion -- References -- 3: Bioinspired Nanoparticles in Cancer Theranostics -- 3.1 Introduction -- 3.2 Novelty of Bioinspired Nanoparticles Based Theranostics -- 3.2.1 Liposomes in Cancer Theranostics -- 3.2.2 Lipid Nanoparticles in Cancer Theragnostic -- 3.2.2.1 Solid Lipid Nanoparticles (SLNs) -- 3.2.2.2 Nano-Structured Lipids (NLCs) -- 3.2.2.3 Lipid Nanocapsules (LNCs) -- 3.2.3 Protein-Based Nanoparticles for Cancer Theranostics -- 3.2.4 Virus like Nanoparticles in Cancer Theranostics -- 3.2.5 Inorganic and Bionanoparticles in Cancer Theranostics -- 3.3 Conclusions and Future Perspectives -- References -- 4: Nanomedicines for Solid Tumors: Current Status, Challenges, and Future Prospects -- 4.1 Introduction -- 4.2 Possible Factors that Initiate Cancer Growth -- 4.2.1 Age -- 4.2.2 Cancer Causing Elements -- 4.2.3 Immunosuppression -- 4.2.4 Infectious Agents -- 4.2.5 Radiation -- 4.3 Tumor Classification Based on Tissue of Origin -- 4.4 Existing Treatment Options Available for Cancer -- 4.5 Description of Solid Tumor -- 4.6 Nanomedicine -- 4.6.1 Unlocking Novel Cancer Applications Exploited in the Field of Nanomedicine -- 4.7 Fabrications of Nanocarrier for Drug Delivery. 4.8 Targeted Delivery of Nanocarrires to the Tumor Niche as Well as Solid Tumor -- 4.8.1 Drug Targeting Mechanisms and Surface Functionalization of Nanocarriers Aiding Nanomedicine Based Technologies in Solid ... -- 4.9 Nanoscience Based Imaging Technologies in the Detection of Solid Tumors -- 4.9.1 Photodynamic Nanomedicine in the Treatment of Solid Tumors -- 4.10 Nanomedicine and Solid Tumor Heterogenecity -- 4.11 Nanomedicine in Solid Tumors: PROS and CONS? -- 4.11.1 PROS -- 4.11.2 CONS -- 4.12 Discussion -- 4.13 Future Perspective -- References -- 5: Nanomaterials for Early Cancer Diagnostics -- 5.1 Introduction -- 5.2 Cancer and Biomarkers -- 5.2.1 Early Detection of Prostate Cancer -- 5.2.2 Early Detection of Breast Cancer -- 5.2.3 Early Detection of Lung Cancer -- 5.2.4 Early Detection of Liver Cancer -- 5.2.5 Early Detection of Oral Cancer -- 5.2.6 Early Detection of Pancreatic Cancer -- 5.2.7 Early Detection of Ovarian Cancer -- 5.2.8 Early Detection of Human Cervical Cancer -- 5.2.9 Early Detection of Bladder Cancer -- 5.2.10 Early Detection of Head and Neck Cancer -- 5.2.11 Early Detection of Colon Cancer -- 5.3 Conclusion -- References -- 6: Role of Nanomedicine for Cancer Immunotherapy -- 6.1 Introduction -- 6.2 Improving Cellular-Mediated Immunotherapy -- 6.2.1 Combining Therapeutic Agents to Immune Cells -- 6.2.2 Directing Therapeutic Drugs to Immune Cells -- 6.2.3 Delivery of Gene in Lymphocytes -- 6.3 Delivery Mechanism of Nanoparticle Therapeutics -- 6.3.1 Stimulating Immunogenic Cell Death (ICD) -- 6.3.1.1 Nanosized Drug Carriers -- 6.3.1.2 Nanopulse Stimulation -- 6.3.2 Enhanced Presentation of Ligands to Immune Cells -- 6.3.3 Chronological Regulation of Immunostimulation -- 6.4 Modulation in Pharmacokinetics of Immunotherapy Agents -- 6.5 Targeting Myeloid Cells -- 6.6 Targeting Stromal Cell in TME. 6.7 Limitations of Nanomedicines in Cancer Immunotherapy -- 6.8 Conclusion and Future Perspectives -- References -- 7: Targeting Tumor Microenvironment Through Nanotheranostics -- 7.1 Introduction -- 7.2 The Tumor Microenvironment (TME) and its Components -- 7.2.1 Cells of the Immune System -- 7.2.1.1 The T Cells -- 7.2.1.2 The B Cells -- 7.2.1.3 Tumor Associated Macrophages (TAMs) -- 7.2.1.4 Tumor Associated Neutrophils (TANs) -- 7.2.1.5 Natural Killer (NK) Cells -- 7.2.1.6 Cancer Associated Fibroblasts (CAFs) -- 7.2.2 The Extracellular Matrix (ECM) and Surrounding Cells -- 7.2.2.1 The Adipocytes -- 7.2.2.2 The Pericytes -- 7.2.2.3 Matrix Metalloproteases (MMPs) and Other Proteases -- 7.2.2.4 The Endothelial Cells -- 7.2.3 The TME, Inflammation, and Cancer -- 7.2.4 Hypoxia in the TME -- 7.3 The TME as an Attractive Therapeutic Target in Cancer -- 7.4 Cancer Nanotheranostic Agents that Target the TME -- 7.4.1 Metallic Nanoparticles (NPs) -- 7.4.2 Magnetic Nanoparticles (MNPs) -- 7.4.3 Mesoporous Silica Nanoparticles (MSiNPs) -- 7.4.4 Nano-Graphenes (NGs) -- 7.4.5 Polymeric-Based Nanotheranostic Particles (PNPs) -- 7.4.6 Lipid-Based Nanotheranostic Particles (LNPs) -- 7.4.7 Protein-Based Nanotheranostic Particles (PNPs) -- 7.4.8 Viral-Based Nanotheranostic Particles (VLPs) -- 7.4.9 DNA-Based Cancer Nanotheranostic Platform -- 7.5 Visualizing Cancer Through Nanotheranostics -- 7.5.1 Magnetic Resonance Imaging (MRI) -- 7.5.2 Photoacoustic Imaging (PAI) -- 7.5.3 Optical Imaging -- 7.5.4 Nuclear Imaging -- 7.6 Nanotheranostics for the Detection of Cancer Biomarkers -- 7.6.1 Labeling Nanoparticles with Conjugates -- 7.6.1.1 Chemical Crosslinking -- 7.6.1.2 Biotin/Avidin Conjugation -- 7.6.1.3 Click Chemistry -- 7.6.2 Target Moieties for Identification of Cancer Biomarkers -- 7.7 Conclusion and Future Direction -- References. 8: Therapeutic Applications of Noble Metal (Au, Ag, Pt)-Based Nanomedicines for Melanoma -- 8.1 Introduction -- 8.1.1 Melanoma -- 8.1.1.1 Global Statistics and Market -- 8.1.1.2 Treatment Strategies -- 8.1.2 Nanotechnology in Melanoma -- 8.1.2.1 Nanoparticles for Melanoma -- 8.1.2.2 PAMAM -- 8.1.2.3 Zinc Oxide Nanoparticle -- 8.1.2.4 Titanium Dioxide Nanoparticle -- 8.1.2.5 Vanadium Pentoxide Nanoparticle -- 8.1.2.6 Copper Prussian Blue Nanoparticle -- 8.2 Importance of Noble Metal Nanoparticles in Biomedicine -- 8.3 Role of Noble Metals (Au, Ag, Pt) in Treatment of Melanoma -- 8.3.1 Gold (Au) Nanoparticles -- 8.3.1.1 Drug Delivery -- 8.3.1.2 Gene Delivery and Immunotherapy -- 8.3.1.3 Biosynthesized Gold Nanoparticles -- 8.3.1.4 Imaging -- 8.3.1.5 Photothermal and Photodynamic Therapy -- 8.3.2 Silver (Ag) Nanoparticles -- 8.3.3 Platinum (Pt) Nanoparticles -- 8.4 Toxicity of Noble Metal Nanoparticles -- 8.5 Challenges and Future Perspectives -- 8.6 Conclusion -- References -- 9: Ethics in Nanomedicine -- 9.1 Introduction -- 9.2 Nanomedicine -- 9.3 Difference Between Nanotechnology and Nanomedicine -- 9.4 Hype Versus Reality of Nanomedicine -- 9.5 Nondiscrimination and Integrity of Nanomedicine -- 9.6 The Potentiality of Nanomedicine -- 9.7 Biocompatibility and Toxicity of Nanostructures -- 9.8 Demand of the Nanomedicine in Market -- 9.9 Nanomedicine and Ethical Concerns -- 9.9.1 Ethical Problems Associated with Translational Research Involving Nanomedicine -- 9.9.2 Ethical Problems in Personalized and Regenerative Therapy with Nanomedicine -- 9.9.3 Ethical Concerns of Medical Surveillance -- 9.9.4 Ethical Challenges Inherent to Nanomedicine Applications -- 9.9.5 Social Ethics in Public Health Systems -- 9.9.5.1 Impact of Nanotechnology in Developing Nations -- 9.9.5.2 Impact of Nanotechnology on Laborers and Managerial Issues. 9.10 Future Perspectives. |
| Record Nr. | UNINA-9910488707403321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanomedicine in Brain Diseases : Principles and Application / / edited by Xue Xue
| Nanomedicine in Brain Diseases : Principles and Application / / edited by Xue Xue |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (XIV, 313 p. 103 illus., 91 illus. in color.) |
| Disciplina | 611.01816 |
| Soggetto topico |
Molecular biology
Nanotechnology Diagnosis, Laboratory Molecular Medicine Laboratory Medicine Malalties cerebrals Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-13-8731-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction: Nanomedicine in the Brain -- The Strategies of Nanomaterials for Traversing Blood-Brain Barrier -- The Strategies of Nanomaterials for Drug Delivery and Release -- The Strategies of Nanomaterials for Therapy -- The Strategies of Nanomaterials for Diagnostic and Imaging -- Nanoenzyme -- Biomacromolecule-Based Nanomedicine -- Carbon-Based Nanomedicine -- Polymeric Nanomedicine -- Magnetic Nanomedicine -- Boron Neutron Capture Nanomedicines. |
| Record Nr. | UNINA-9910373919503321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanoparticles for rational vaccine design / / Harvinder Singh Gill, Richard W. Compans, editors
| Nanoparticles for rational vaccine design / / Harvinder Singh Gill, Richard W. Compans, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (140 pages) |
| Disciplina | 615.372 |
| Collana | Current topics in microbiology and immunology |
| Soggetto topico |
Vaccines - Design
Vacunes Immunoteràpia Nanopartícules Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-85067-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910495172503321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanotechnology applications in health and environmental sciences / / Necdet Saglam, Feza Korkusuz, Ram Prasad, editors
| Nanotechnology applications in health and environmental sciences / / Necdet Saglam, Feza Korkusuz, Ram Prasad, editors |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (XIV, 439 p. 77 illus., 62 illus. in color.) |
| Disciplina | 610.28 |
| Collana | Nanotechnology in the Life Sciences |
| Soggetto topico |
Nanomedicine
Nanomedicina Nanotecnologia Medi ambient |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-64410-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Diverse Manifolds of Biogenic Nanoparticles in Synthesis, Characterization and Applications -- Impact of Nanoparticles on Human Microbiota -- In-Vitro Applications of Nanoparticles -- Nanoparticles for Anticancer Drug Delivery -- Application of Nanotechnology in the Treatment of Microbial Infections -- Metal Organic Framework: Applications in Nanomedicine -- Recent Advances in Nanomaterial-Based Diagnosis and Treatment -- Nanobiosensors for Biomedical Applications -- Emerging Role of Nanomaterial Assisted Bio-Sensors for Circulating Tumor Cells Detection -- Advanced Functional Polymers for Biomedical Applications -- SERS Sensor Applications in Environmental Analysis and Biotechnology -- Design and Creation of Micro and Nano Environment in Regenerative and Restorative Medicine -- Presenting and Treating Bone Infections Using Silver-Ion Containing Nano-Hydroxyapatite -- Trace Element Containing Nano-HAp for Preventing Musculoskeletal Infections -- Biotechnological Approaches in Maintenance of a Healthy Immune System for Protection Against Diseases -- Production and Characterization of Antibiotic-Containing Nano-Calcium Phosphates -- Lantibiotics Nanotechnology, Bioengineering and Biotechnology -- Microbial Biotechnology and Postmortem Diagnosis -- Clean-Up and Pollution with Nanoparticles: An Environmental Dillemma -- Environmental Myco-Nanobiotechnology and Fungal Bioremediation -- Application of Nanotechnology in Detection and Diagnosis of Plant Diseases -- Index. |
| Record Nr. | UNINA-9910484264003321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
